Statin use in American Indians and Alaska Natives with coronary artery disease

American Journal of Health-System Pharmacy

Volumn 63, Issue 18, 2006, Pages 1717-1722

  Cooke, Catherine E ^a,b,f   Bresette, James L ^c,d   Khanna, Rozina ^e  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c U S PUBLIC HEALTH SERVICE   (United States)

^d INDIAN HEALTH SERVICE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f NONE   (United States)

Author keywords

Age; Antilipemic agents; Compliance; Coronary disease; Drug use; Ethnic groups; Patients; Sex

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE; AGED; AMERICAN INDIAN; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG USE; ESKIMO; FEMALE; GENDER; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION POSSESSION RATIO; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY;

EID: 33748800022     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050517     Document Type: Article

References (33)

1. American Heart Association. Heart disease and stroke statistics-2005 update. Dallas, TX: American Heart Association; 2005:4,12.
2. Centers for Disease Control and Prevention. Disparities in premature deaths from heart disease-50 states and the District of Columbia, 2001. MMWR Morb Mortal Wkly Rep. 2004; 53:121-5.
3. Welty TK, Rhoades DA, Yeh F et al. Changes in cardiovascular disease risk factors among American Indians: the Strong Heart Study. Ann Epidemiol. 2002; 12:97-106.
4. Howard BV, Welty TK, Fabsitz RR et al. Risk factors for coronary heart disease in diabetic and nondiabetic Native Americans: the Strong Heart Study. Diabetes. 1992;41(suppl 2):4-11.
5. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290:199-206.
6. Howard BV, Lee ET, Fabsitz RR et al. Diabetes and coronary heart disease in American Indians. The Strong Heart Study. Diabetes. 1996; 45(suppl 3):S6-13.
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-421.
8. Grundy SM, Cleeman JI, Merz NB et al. NCEP report. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39.
9. Smith SC, Blair SN, Bonow RO et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001; 104:1577-9.
10. Wei L, Wang J, Thompson P et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a 6 year follow-up study. Heart. 2002; 88:229-33.
11. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998; 279:1458-62.
12. Johnsrud M, Schafermeyer KW. Measuring adherence and persistence in drug therapy. J Manag Care Pharm. 2002; 8:204-6.
13. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care. 2001; 10:42-5.
14. Tonstad S, Rosvold EO, Furu K et al. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med. 2004; 255:494-502.
15. Steingart RM, Packer M, Hamm P et al. Sex differences in the management of coronary artery disease. N Engl J Med. 1991; 325:226-30.
16. Miller M, Byington R, Hunninghake D et al. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med. 2000; 160:343-7.
17. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol. 2003; 55:604-8.
18. DeWilde S, Carey IM, Bremmer SA et al. Evolution of statin prescribing 1994-2001: a case of agism but not sexism? Heart. 2003; 89:417-21.
19. Aronow HD, Novaro GM, Lauer MS et al. In hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization. Arch Intern Med. 2003; 163:2576-82.
20. Howell N, Trotter R, Mottram DR et al. Compliance with statins in primary care. Pharm J. 2004; 272:23-6.
21. Sung JC, Nichol MB, Venturini F et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. 1998; 4:1421-30.
22. Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995; 332:1125-31.
23. Grant RW, O'Leary KM, Weilburg JB et al. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004; 164:2343-8.
24. Benner JS, Tierce JC, Ballantyne CM et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics. 2004; 22(suppl3):13-23.
25. American Heart Association. Statistics you need to know, statistics on medication. www.americanheart.org/presenter. jhtml?identifier=107 (accessed 2005 May 13).
26. Chapman NR, Fotis MA, Yarnold PR et al. Pharmacist interventions to improve the management of coronary artery disease. Am J Health-Syst Pharm. 2004; 61:2672-8.
27. Tsuyuki RT, Johnson JA, Teo KK et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med. 2002; 162:1149-55.
28. Ali F, Laurin MY, Lariviere C et al. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol. 2003; 10:101-6.
29. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc. 2000; 40:157-65.
30. Cording MA, Engelbrecht-Zadvorny EB et al. Development of a pharmacist-managed lipid clinic. Ann Pharmacother. 2002; 36:892-904.
31. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm. 2003; 9:269-73.
32. Mazzolini TA, Irons BK, Schell EC et al. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers. J Manag Care Pharm. 2005; 11:763-71.
33. Satter DE, Veiga-Ermert A, Burhansstipanov L et al. Communicating respectfully with American Indian and Alaska Natives: lessons from the California Health Interview Survey. J Cancer Educ. 2005; 20:49-51.